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Health Service and Policy Research Column
Diabetes management before and after cancer diagnosis: missed 
opportunity
Nengliang Yao1, Fabian T. Camacho2, Askar S. Chukmaitov1, Steven T. Fleming3, Roger T. Anderson2
1Department of Healthcare Policy and Research, Virginia Commonwealth University, College of Medicine, Richmond, VA 23298, USA; 2College of 
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Background: Few studies have examined the management of comorbidities in cancer patients. This study used 
population-based data to estimate the guideline concordance rates for diabetes management before and after cancer 
diagnosis and examined if diabetes management services among cancer patients was associated with characteristics 
of the hospital where the patient was treated.
Methods: We linked 2005-2009 Medicare claims data to information on 2,707 breast and colorectal cancers 
patients in state cancer registry files. Multivariate logistic regression models examined hospital characteristics 
associated with receipt of diabetes management care after cancer diagnosis.
Results: The rates of HbAlc testing, LDL-C testing, and retinal eye exam decreased from 72.7%, 79.6%, and 
57.9% before cancer diagnosis to 58.3%, 69.5%, and 55.8% after diagnosis. The pre- and post-diagnosis diabetes 
management care was not significantly different by hospital characteristics in the bivariate analysis except for that 
the distance between residence and hospital was negatively related to retinal eye exam after diagnosis (P<0.05). The 
multivariate analysis did not identify any significant differences in diabetes management care after cancer diagnosis 
by hospital characteristics.
Conclusions: Cancer patients received fewer diabetes management care after diagnosis than prior to diagnosis, 
even for those who were treated in large comprehensive centers. This may reflect a missed opportunity to connect 
diabetic cancer patients to diabetes care. This study provides benchmarks to measure improvements in comorbidity 
management among cancer patients.
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Introduction
Because of advances in early detection and treatment 
methods, the overall cancer death rate has steadily 
declined since the early 1990s and the 5-year survival rate 
is now 68%, up from 49% in the 1970s (1). In 2013, the 
cancer survivor population in the US was estimated to be 
14 million, and a great number of them have comorbid 
conditions. Comorbid conditions such as diabetes are major 
threats to life for breast and colorectal cancer survivors (2,3). 
If diabetes is not well controlled, it can lead to stroke, heart 
disease, and disabilities, such as vision problems, kidney 
failure, or amputations of the foot or leg. A systematic 
review found that breast and colorectal cancer patients 
with diabetes also had worse clinical outcomes than those 
without diabetes (2). In addition, pre-existing diabetes is 
more prevalent in individuals with breast and colorectal 
cancer than other Americans (4,5).
There is well-founded concern that cancer-related 
services may compete with ongoing delivery of primary 
health care services, such as diabetes care, as patients with 
cancer often undergo treatment that includes multiple 
services over weeks or months delivered by medical 
specialties (6). This care pattern may disrupt usual care 
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by overriding health concerns or from specialists “taking 
over” responsibility for a patient’s health care while cancer 
is being managed. However, it can also be postulated that 
since cancer patients have more interactions with the 
healthcare system after cancer diagnosis than pre-diagnosis, 
they would have additional opportunities to receive 
recommended diabetic management services (6-8). A recent 
study found that diabetic cancer patients received similar 
diabetic care relative to diabetic patients without cancer 
in a health maintenance organization (6). Another study 
found that survivors with diabetes enrolled in traditional 
fee-for-service Medicare were significantly less likely than 
diabetic patients without cancer to have regular diabetes 
examinations (7). These results potentially indicate that the 
health care delivery model may play a role in coordinating 
diabetes care.
This study examined the influence of cancer care delivery, 
such as characteristics of the hospital where the patient was 
treated, and the patient’s overall reliance on that hospital 
for their cancer on diabetes care among cancer patients 
with Medicare insurance. We expected that physicians at 
different hospitals would have different levels of motivation 
and capacity to recommend management services to cancer 
patients with diabetes, which could produce heterogeneity 
in diabetes care among survivors. In the present study, we 
compared the quality of diabetes management delivered 
to diabetic patients who had cancer surgery in small 
hospitals and patients treated in large cancer centers, and 
considered the effects of care fragmentation and distance on 
the outcome. The present study provides new insights by 
using a population-based sample of Medicare beneficiaries 
diagnosed with breast or colorectal cancer to examine the 
effect of several characteristics of the hospital where the 
patient was treated on measures of diabetes management 
quality outcomes before and after diagnosis. 
Methods
Data and study cohort
This study is a part of a large project to study the pattern 
and quality of cancer care in breast and colorectal cancer 
patients living in Appalachian counties in North Carolina, 
Ohio, Kentucky, and Pennsylvania (9,10). This project 
obtained state central cancer registry data on breast and 
colorectal cancer incidence for 2006-2008. Patient data 
were linked to Medicare enrollment files using patients’ 
social security numbers, first and last names, gender, and 
dates of birth. These data are likely to have complete claims 
during 2005-2009 for patients not enrolled in a health 
maintenance organization. Data that were similarly linked 
have been used extensively in cancer care research (11-14).
Patients age 21 or older diagnosed with a first primary 
breast or colorectal cancer in 2006-2008 were identified 
in the linked data. The cancer registry data recorded the 
sequence number of reported tumors of each patient. We 
included those enrolled 1 year before and 1 year after 
diagnosis in both Medicare parts A (hospital insurance) and 
B (medical insurance). Cases with enrollment in Medicare 
Advantage or HMO involvement during the 2-year time 
frame were excluded. Cases with prior cancer diagnosis 
were excluded. Autopsy cases and cases where death was 
recorded within 1 year from diagnosis were excluded. Of 
these, 2,907 patients were diagnosed with diabetes 1 year 
before their cancer diagnosis and received surgery 6 months 
after cancer diagnosis. We then identified the facility where 
colorectal cancer surgery was conducted using the reporting 
hospital fields from the cancer registries data together with 
the “class of case” variable indicating if the reporting facility 
was the treatment facility. In addition we supplemented 
this identification by searching for treatment facility using 
Medicare claims files (Table S1). This resulted in 2,707 
patients in the final sample (Figure 1).
Diabetes management services
We assessed three measures of diabetes technical quality 
and clinical outcomes based on definitions proposed by the 
Diabetes Quality Improvement Program (DQIP) and 2004 
Health Plan Employer Data and Information Set (HEDIS): 
glycated hemoglobin (HbAlc) testing every 6 months, 
serum cholesterol level (LDL-C) testing every year, and 
dilated retinal eye exam every year (15,16). For example, 
healthcare systems, such as Partners HealthCare, also use 
these three measures to develop their report cards (17). 
HbA1c is a lab test that shows the average level of blood 
sugar (glucose) and registry cancer diagnosis variables 
(Table S1). 
Explanatory variables
The main explanatory variables of concordance concerned 
characteristics of the hospital where surgery was completed. 
Most patients completed their adjuvant therapy in the 
hospital or cancer center where surgery was completed 
or the outpatient clinics of these hospitals. We calculated 
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volume of care variables based on all 2008 national 
Medicare claims associated with the hospitals in our 
database. All claims with procedure codes for breast and 
colorectal cancer surgical codes were singled out, and all 
non-duplicate unique claims for the hospital were summed. 
Surgery volume quartiles calculated over the sample were 
assigned to patients depending on the type of cancer (e.g., 
colorectal cancer resection volume quartiles for patients 
with colorectal cancer diagnosis). A volume of diabetes care 
variable was calculated using all available 2008 Medicare 
claims associated with facilities surrounding the study 
region, including claims not associated with patients 
within the sample. For each facility, all claims during 2008 
associated with a diabetes ICD-9 diagnosis initiating with 
“250” were selected, duplicates were removed, and the 
number of unduplicated claims was then summed to arrive 
at a volume variable.
Number of beds, ownership information, and service mix 
(the number of high tech services such as acute renal dialysis, 
burn care unit, organ transplant) were obtained from the 
Provider of Service (POS) file available from the Centers for 
Medicare and Medicaid Services (CMS) particular to the year 
2007. Commission on Cancer (CoC) accreditation status 
was obtained by consulting accreditation history (particular 
to 2007) from the web site facility locator (18). The ratio 
of total Medicaid inpatient days to total inpatient days 
was extracted from Healthcare Cost Report Information 
(HCRIS) data (19). We used the 2010 American Hospital 
Association survey data to extract information of the 
organizational structure of the hospital (centralized, 
centralized physician/insurance, decentralized, freestanding, 
independent, and moderately centralized). Patients’ 
residential distance from the surgical site was calculated as 
driving distance from the listed patient residential address 
to the surgical facility location. The addresses of both 
the patients and facilities were obtained from the Cancer 
Registry patient data and Medicare Provider of Service file. 
Driving distances between the addresses were geocoded 
and calculated with ArcGIS using the ESRI Street Map Pro 
network file.
Patient level variables were extracted from the cancer 
registry data and included age at diagnosis, gender, race/
ethnic status, derived America Join Committee on Cancer 
(AJCC) stage grouping, tumor size, cancer site, surgery, 
and state of residence. A two-level diabetes severity score 
was calculated. Patients with low risk diabetes did not 
have complications or use insulin. Patients on insulin 
and patients with diabetes complications and diabetic 
ketoacidosis hospital episodes were classified as intermediate 
to high risk. A comorbidity score was calculated using the 
ACE-27 measure (excluding diabetes from the metric) as it 
captures more comorbidities than the Charlson comorbidity 
index (20). The four-level overall score ranges from 0 (no 
comorbidity burden) to 3 (severe comorbidity burden). In 
addition, patients were also classified by whether or not 
they received surgery at the facility where their cancer was 
diagnosed. (Patient’s pattern of use of facilities for cancer 
care were determined from NAACCR coding on ‘class 
of case’ reported for the surgical facility, and from CMS 
POS data where place of service was identified. Patients 
were initially defined as have ‘sole source’ cancer care 
if they were coded as class of case “1” (Diagnosis at the 
accessioning facility, and all or part of the first course of 
Colorectal and female breast cancers with diagnostic 
confirmation, excluding autopsies (n=50,202)
Limited to cases with 1 year Part A&B enrollment 
pre/post diagnosis in Medicare (n=22,341)
Excluded cases enrolled in an HMO or Medicare 
Advantage Program and those with mismatching 
gender and birthdates between registry and 
Medicare sources (n=14,166)
Limited to tumors reported 
first per patient (n=10,819)
Surviving at least 1 year after diagnosis (n=10,775)
Limited to cases that were diagnosed with diabetes 
1 year before their cancer diagnosis and received 
surgery in six months after cancer diagnosis 
(n=2,907)
Limited to cases that are reported by the 
colorectal cancer surgery hospital (n=2,707)
Figure 1 Patient selection criteria.
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treatment was performed). CMS claims data were used to 
reclassify patients with class of case =1 as having fragmented 
care if they received chemotherapy services from a location 
other than the surgical facility site.) County level contextual 
variables where assigned to each patient based on residence 
at time of diagnosis. Data of contextual variables were 
drawn from the American Community Survey, Area 
Resource Files, and Appalachian Regional Commission 
(21-23). Important variables of socioeconomic status, such 
as family income and educational level, were not accessible 
due to data limitations.
Multivariate analysis
Association of post-diagnosis concordance measures with 
facility characteristics was examined using bivariate and 
multivariate analysis, in all cases adjusting for pre-diagnosis 
measures. For bivariate analysis, significance tests were 
conducted using logistic regression with post-diagnosis 
concordance as the dependent variable and examining the 
Wald test P values testing the bivariate association. For the 
multivariate analysis, all facility variables were included 
as independent variables in the model and the association 
with each variable was tested using Wald tests P values. 
In addition to previous concordance measures, selected 
demographics, tumor factors, and county level factors were 
included in the regression model using sequential forward 
regression and choosing the best fit regression model with 
the smallest Akaike Information Criteria. 
Trend analysis 
The follow-up period in the multivariate analyses was 
relatively short but used a relatively large sample size. In 
order to examine the pattern of diabetes management care 
over a relatively long time, we used only those patients 
who were continually enrolled in traditional Medicare 
for 3 years to conduct the trend analysis (N=1,665). A 
generalized estimating equations (GEE) main effect 
regression was conducted. Independent variables in the 
model included corresponding management care prior to 
diagnosis, time period (treated as a categorical variable), age 
groups, gender, race, comorbidity, diabetes severity, stage 
at diagnosis, tumor size, and type of surgery. Observations 
were clustered by patient and the unstructured covariance 
was chosen. Further, observations with missing data in the 
covariates were excluded. Expected probabilities of care 
were calculated by evaluating probabilities predicted by 
the model at the mean values for continuous variables and 
balanced rates for categorical variables.
 
Results
Table 1 shows that the median age of our sample was 
74.4 years old. Our sample contained proportionately more 
female patients (76.5%). Both breast and colorectal cancer 
patients were predominately white (95.5%). Most patients 
(78.7%) were diagnosed with tumors smaller than 5 cm in 
size with early stage diseases (78.7%). Comorbidity burden 
among these patients was substantial: 90.5% of cancer 
patients had at least some level of burden, and nearly 19% 
had ‘severe’ comorbidity burden, which is associated with 
decreased survival after surgery. Almost 42% of these cancer 
patients had severe diabetes.
The overall rates of HbAlc testing, LDL-C testing, 
and retinal eye examinations before cancer diagnosis were 
72.7%, 79.6%, and 57.9%, respectively (Table 2). The 
rates of HbAlc testing, LDL-C testing, and retinal eye 
examinations decreased after cancer diagnosis (58.3%, 
P<0.001; 69.5%, P<0.001; and 55.8%, P<0.05 respectively). 
In addition, there were no significant differences in 
guideline-concordant diabetes care before or after cancer 
diagnosis by characteristics of the hospital where the patient 
was treated such as CoC designation, number of beds, 
ownership, the ratio of Medicaid inpatient days, surgery 
volume, diabetes service volume, medical service mix, and 
organizational structure. We only found that the distance 
between the patient’s residence and hospital was negatively 
related to retinal eye testing (P value =0.0242). 
When patient and tumor characteristics were controlled, 
the strongest predictor of receiving diabetes care after 
cancer diagnosis was if the patient had received the same 
service before cancer diagnosis, which is consistent across 
three outcome measures (Table 3). For example, patients 
who received LDL-C testing before cancer diagnosis had 
five times the odds of having an LDL-C testing after cancer 
diagnosis when compared to those who didn’t receive an 
LDL-C testing before cancer diagnosis. There weren’t any 
significant differences in HbAlc testing, LDL-C testing, 
and retinal eye exam care before or after cancer diagnosis by 
hospital characteristics.  
The trend analyses (Table 4) showed that the predicted 
probability of HbAlc testing, LDL-C testing, and retinal 
eye examinations decreased the first year after cancer 
diagnosis but then increased in the second year after 
diagnosis. For example, the predicted probability of 
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HbA1c testing decreased from 0.73 before diagnosis to 
0.57 at the first 6 months after diagnosis, and gradually 
increased in the next year and a half (0.64, 0.66, 0.67, 
P<0.0001). The other two measures followed a similar 
trend pattern as that for HbAlc testing, but did not reach 
statistical significance (P=0.0002 for LDL-C testing and 
P=0.0694 for retinal eye exam).
Discussion
This study provides population-based estimates of diabetes 
management care before and after cancer diagnosis. 
Although scientific attention to diabetes care among 
cancer patients is increasing (2,6-8), this is the first study to 
compare diabetes management care before and after cancer 
diagnosis and examine if diabetes management care among 
cancer patients was associated with the characteristics 
of the hospital where cancer surgery was performed. 
We found that cancer patients received fewer diabetes 
management services after diagnosis than prior to diagnosis. 
The predicted probability of diabetes management tests 
decreased at first after diagnosis and gradually increased 
thereafter. It does not appear that there is a particular 
advantage to being treated for cancer in a larger or CoC 
designated hospital or those with higher surgical volumes, 
at least in terms of concordance with diabetes guidelines. 
Table 1 Demographic and tumor characteristics and county-level 
factors (n=2,707)
Characteristics N (%)
Gender
Female 2,072 (76.54)
Male 635 (23.46)
Race/ethnicity
White non-hispanic 2,585 (95.50)
Other 122 (4.51)
Comorbidity (non-diabetes)
0 256 (9.46)
I 1,309 (48.36)
II 617 (22.79)
III 525 (19.39)
Diabetes severity
Low risk 1,574 (58.15)
Intermediate to high risk 1,133 (41.85)
State of residence
Kentucky 350 (12.93)
North Carolina 379 (14.00)
Ohio 568 (20.98)
Pennsylvania 1,410 (52.09)
Metropolitan status
Metro 1,367 (50.50)
Non-metro 1,340 (49.50)
AJCC stage at diagnosis
Stage 0 349 (13.37)
Stage I 892 (34.16)
Stage II 815 (31.21)
Stage III 441 (16.89)
Stage IV 114 (4.37)
Tumor size (cm)
<0.5 76 (3.27)
0.5-1 217 (9.35)
1-2 580 (24.98)
2-3 429 (18.48)
3-4 288 (12.40)
4-5 237 (10.21)
>5 495 (21.32)
Primary site
Breast 1,416 (52.31)
Colon 1,052 (38.86)
Rectosigmoid 80 (2.96)
Rectum 159 (5.87)
Table 1 (continued)
Table 1 (continued)
Characteristics N (%)
Surgery type
Breast conserving surgery 838 (30.96)
Colorectal cancer surgery 1,291 (47.69)
Mastectomy 578 (21.35)
County economic status
Competitive 461 (17.03)
Transitional 1,719 (63.50)
At risk 296 (10.93)
Distressed 231 (8.53)
Population with high school diploma 
(weighted meanǂ) (%)
87.95
White not hispanic (weighted meanǂ) (%) 86.69
Population in poverty (weighted meanǂ) (%) 13.33
No. of general practice practitioners per 
100,000 people (weighted meanǂ)
242.14
ǂ, weighted by the 2,000 census population number. AJCC, 
American Joint Committee on Cancer.
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Table 2 Concordance rates of diabetes management care by characteristics of the hospital where the patient was treated
Characteristics N (%)
HBA1c LDL-C Retinal eye
Pre (%) Post (%) Pre (%) Post (%) Pre (%) Post (%)
Total 2,707 72.70 58.26 79.60 69.49 57.90 55.82
CoC Designation
CoC 1,723 (63.65) 73.13 57.37 79.22 69.94 58.56 57.11
Non-CoC 984 (36.35) 71.95 59.86 80.18 68.70 56.71 53.56
No. of beds
<100 327 (12.08) 74.62 63.61 79.51 70.03 57.49 55.96
100-199 562 (20.76) 74.38 59.96 80.78 70.28 57.12 55.34
200-499 1,279 (47.25) 71.23 55.98 79.91 68.88 57.54 54.65
>500 539 (19.91) 73.28 58.63 77.55 69.76 59.74 59.00
Facility type
For profit 128 (4.73) 75.00 55.47 84.38 73.44 57.81 52.34
Government 193 (7.13) 72.02 59.59 79.27 68.91 55.96 51.81
Not for profit 2,386 (88.14) 72.63 58.30 79.34 69.32 58.05 56.33
Medicaid inpatient days ratio
<10% 1,498 (55.61) 71.36 56.61 78.70 68.69 58.68 57.48
10-20% 883 (32.78) 74.86 61.38 81.09 69.54 58.10 55.15
>20% 313 (11.62) 72.84 57.51 79.87 73.48 53.67 50.48
Surgery volume
1st quartile (0-13 CRC, 0-23 BC) 644 (23.79) 73.60 60.71 78.11 66.61 55.90 55.59
2nd quartile (14-24 CRC, 24-42 BC) 726 (26.82) 71.07 56.06 78.93 70.39 57.85 53.58
3rd quartile (25-42 CRC, 43-63 BC) 678 (25.05) 74.19 58.11 81.71 70.50 57.23 56.05
4th quartile (43+ CRC, 64+ BC) 659 (24.34) 72.08 58.42 79.51 70.26 60.55 58.27
Distance to facility*
1st  quartile (0-4.6 mi) 704 (26.01) 73.15 59.38 78.55 69.89 62.22 59.66
2nd quartile (4.6-10.4 mi) 694 (25.64) 69.60 58.65 75.36 65.56 56.63 57.35
3rd quartile (10.4-22.3 mi) 682 (25.19) 73.02 57.33 81.96 70.38 59.82 56.60
4th quartile (>22.4 mi) 627 (23.16) 75.28 57.58 82.78 72.41 52.31 48.96
Diabetes service volume [No. of claims]
1st quartile [0-150] 662 (24.46) 74.47 60.73 81.72 68.88 58.01 54.83
2nd quartile [150-310] 661 (24.43) 73.68 59.76 80.03 69.74 54.16 53.10
3rd quartile [310-180] 742 (27.42) 72.64 57.55 78.17 67.92 61.05 57.95
4th quartile [>581] 641 (23.69) 70.05 54.91 78.47 71.76 57.88 57.25
No. of high tech medical services
1st quartile [0-6] 613 (22.64) 75.53 61.50 80.91 69.98 57.79 54.65
2nd quartile [7-8] 800 (29.55) 71.13 56.75 77.88 69.00 54.75 53.50
3rd quartile [9-10] 534 (19.73) 70.79 56.93 78.09 65.54 58.61 58.05
4th quartile [11-18] 760 (28.08) 73.42 58.16 81.32 72.37 60.92 57.63
Health system
Centralized health system 134 (4.95) 72.39 60.45 82.84 72.39 60.45 59.70
Centralized physician/insurance health system  281 (10.38) 75.44 58.36 77.22 71.17 61.57 61.92
Decentralized health system 382 (14.11) 68.59 55.50 79.06 69.63 53.93 50.79
Freestanding hospital system 1,113 (41.12) 74.03 58.40 79.87 69.63 56.24 54.63
Independent hospital system 120 (4.43) 65.83 53.33 79.17 64.17 64.17 55.83
Moderately centralized health system 677 (25.01) 72.97 59.97 79.76 68.83 59.68 57.31
*P=0.0242 for retinal eye exam. P values are based on Wald contrasts from logistic regression adjusting examining overall association after adjusting for 
previous value before diagnosis. Only showing the P values that are smaller than 0.05. CoC, Commission on Cancer. 
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Table 3 Odds ratios (95% CI) of receiving diabetes management care after cancer diagnosis
Characters HBA1c LDL-C Retinal eye
Pre-diagnosis 4.85 (4.00-5.88) 5.10 (4.13-6.30) 4.83 (4.06-5.74)
COC designation P=0.6429 P=0.5592 P=0.2650
COC 1.17 (0.92-1.50) 0.93 (0.71-1.20) 1.15 (0.90-1.47)
Non-COC 1.00 (reference) 1.00 (reference) 1.00 (reference)
No. of beds P=0.7653 P=0.2369 P=0.4343
<100 1.04 (0.64-1.69) 1.06 (0.63-1.77) 1.11 (0.69-1.81)
100-199 1.00 (0.69-1.45) 0.88 (0.59-1.32) 1.16 (0.80-1.68)
200-499 0.90 (0.68-1.20) 0.79 (0.58-1.08) 0.93 (0.70-1.23)
>500 1.00 (reference) 1.00 (reference) 1.00 (reference)
Facility type P=0.7777 P=0.4348 P=0.8227
For profit 0.85 (0.54-1.35) 1.06 (0.64-1.75) 0.91 (0.58-1.43)
Government 1.03 (0.70-1.52) 1.31 (0.87-1.98) 0.90 (0.62-1.33)
Not for profit 1.00 (reference) 1.00 (reference) 1.00 (reference)
Medicaid bed days ratio P=0.0669 P=0.1666 P=0.8526
<10% 1.02 (0.72-1.46) 0.69 (0.47-1.02) 1.09 (0.79-1.50)
10-20% 1.29 (0.91-1.83) 0.72 (0.49-1.05) 1.06 (0.76-1.47)
>20% 1.00 (reference) 1.00 (reference) 1.00 (reference)
Surgery volume P=0.7548 P=0.5239 P=0.2559
Low volume quartile 0.89 (0.62-1.29) 0.99 (0.67-1.46) 1.03 (0.72-1.48)
2nd quartile  0.86 (0.64-1.14) 1.18 (0.87-1.61) 0.82 (0.61-1.09)
3rd quartile  0.90 (0.69-1.17) 1.13 (0.86-1.50) 1.00 (0.77-1.30)
High volume quartile 1.00 (reference) 1.00 (reference) 1.00 (reference)
Distance to facility P=0.2086 P=0.3735 P=0.4245
Low 1st quartile (0-4.6 mi) 1.28 (0.97-1.70) 1.03 (0.77-1.38) 1.26 (0.95-1.67)
2nd quartile (4.6-10.4 mi) 1.31 (0.99-1.73) 0.83 (0.62-1.11) 1.20 (0.91-1.58)
3rd quartile (10.4-22.3 mi) 1.11 (0.85-1.46) 0.93 (0.70-1.24) 1.18 (0.90-1.54)
High 4th quartile (>22.4 mi) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Diabetes service volume [No. of claims] P=0.5449 P=0.3397 P=0.8921
1st quartile [0-150] 1.18 (0.88-1.58) 0.79 (0.58-1.08) 0.89 (0.67-1.19)
2nd quartile [150-310] 1.23 (0.92-1.63) 0.93 (0.69-1.25) 0.94 (0.71-1.23)
3rd quartile [310-180] 1.09 (0.85-1.41) 0.82 (0.62-1.08) 0.97 (0.75-1.26)
4th quartile [>581] 1.00 (reference) 1.00 (reference) 1.00 (reference)
No. of high tech services P=0.8155 P=0.1591 P=0.8356
1st quartile [0-6]  1.03 (0.80-1.34) 0.98 (0.74-1.30) 0.95 (0.73-1.23)
2nd quartile [7-8]  1.01 (0.79-1.29) 0.96 (0.74-1.25) 0.99 (0.78-1.26)
3rd quartile [9-10]  0.90 (0.68-1.19) 0.73 (0.55-0.98) 1.09 (0.83-1.44)
4th quartile [11-18] 1.00 (reference) 1.00 (reference) 1.00 (reference)
Health system P=0.9342 P=0.7520 P=0.4975
Centralized health system 1.11 (0.70-1.75) 0.89 (0.55-1.45) 1.19 (0.76-1.87)
Centr. phys/ins. health system 0.98 (0.70-1.37) 1.23 (0.86-1.77) 1.13 (0.80-1.58)
Decentralized health system 0.90 (0.66-1.24) 1.09 (0.79-1.52) 0.81 (0.60-1.10)
Freestanding hospital system 0.93 (0.72-1.19) 1.00 (0.77-1.31) 0.95 (0.74-1.22)
Independent hospital system 1.05 (0.65-1.71) 0.85 (0.52-1.39) 0.96 (0.60-1.53)
Moderately centralized health system 1.00 (reference) 1.00 (reference) 1.00 (reference)
Patient characteristics, tumor characteristics, and county-level factors were controlled in the regression; HBA1c model included diabetes severity, cancer 
stage, rural/urban continuum, ARC economic class, and county of residence poverty rate; LDL1c model included cancer stage, age group, county of 
residence poverty rate, and gender; retinal eye model included age, cancer stage, and rural/urban continuum; CoC, Commission on Cancer.
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Although we were not able to measure care coordination, 
the results may suggest that the coordination of care for 
cancer patients with diabetes is neither better nor worse 
for cancer patients treated in the more comprehensive 
cancer treatment hospitals. The overall quality of diabetes 
care after cancer diagnosis was not associated with hospital 
ownership, volume, the number of beds, accreditation, 
safety-net burden, travel distance, diabetes service volume, 
mix of medical care service, or organizational structure. 
This may indicate that hospitals where cancer surgery was 
performed were equally poor in coordinating diabetes care 
with cancer treatment.
There may be several explanations for the decrease in 
diabetes management care quality after cancer diagnosis. 
Cancer patients and their physicians may devote more 
attention to interventions directly linked to cancer-
specific mortality reduction as patients may think cancer 
is their greatest threat to life (8). So, primary care might 
be deterred by their intensive cancer treatment. From 
a provider perspective, cancer care physicians were not 
trained to coordinate care for non-cancer related health 
concerns, and the cancer care guidelines did not mention 
diabetes care (7,24,25). In addition, the Medicare program 
did not provide financial incentives to health professionals 
to coordinate non-cancer related healthcare. Although large 
comprehensive cancer centers were often affiliated with 
medical centers with enormous healthcare resources, they 
may fail to connect diabetic cancer patients to diabetes care. 
Additionally, very few comprehensive cancer centers in the 
US have a diabetes program to help cancer patients cope 
with their pre-existing diabetes (26).
The Patient Protection and Affordable Care Act (PPACA) 
provides a few opportunities for improving non-cancer 
related care coordination. The PPACA authorizes grants 
to support community-based collaborative care networks 
that must be consortiums of health care providers with a 
joint governance structure that provides comprehensive 
coordinated and integrated health care services. The 
Department of Health and Human Services will provide 
grants to create community health teams and medical 
homes that include an interdisciplinary team of health care 
providers which would provide integrated community-based 
care for their patients. These policy changes may help small 
cancer hospitals coordinate with primary care physicians 
in providing diabetes management care to cancer patients. 
It does less to ensure the coordination of care if a patient 
receives cancer treatment in a comprehensive cancer center.
Our study has both strengths and weaknesses. The first 
strength is that we were able to describe diabetes care 
before and after cancer diagnosis in the same cohort of 
patients. Second, the quality of diabetes care before cancer 
diagnosis was very similar among different patient groups 
by hospital characteristics in this study. So, patients were 
probably not selected on the basis of their diabetes care 
before diagnosis. There are also several limitations. We 
can only apply these results to elderly cancer patients in 
a fee-for-service environment. Although we focused on 
elderly cancer patients from four states by design, some 
characteristics of healthcare in these four states are shared 
by other regions of the US. Thus, the importance of our 
findings certainly reaches beyond these four states. The 
follow-up time is short in this study, so we were not able 
to examine long-term diabetes management care quality 
among cancer survivors. We plan to request additional 
data to examine if the diabetes care quality improves in the 
second or third year after cancer diagnosis. Some cancer 
patients may have received adjuvant therapies outside the 
hospital where surgery was completed. Our model did not 
capture the influence of outpatient clinics which are not 
affiliated with the hospital where surgery was conducted. 
Table 4  Predicted probabilities of receiving diabetes 
management care before and after cancer diagnosis (n=1,665)
Variables
Predicted 
probabilities
HBA1c P<0.0001
6 months before cancer diagnosis 0.73
6 months after cancer diagnosis 0.57
Months 7-12 after cancer diagnosis 0.64
Months 13-18 after cancer diagnosis 0.66
Months 19-24 after cancer diagnosis 0.67
LDL-C P=0.0002
1 year before cancer diagnosis 0.80
1 year after cancer diagnosis 0.67
2 years after cancer diagnosis 0.73
Retinal eye P=0.0694
1 year before cancer diagnosis 0.58
1 year after cancer diagnosis 0.55
2 years after cancer diagnosis 0.58
Expected probabi l i t ies of care were calculated by 
evaluating probabilities predicted by model at the mean 
values for continuous variables and balanced rates for 
categorical variables.
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Our analysis relies on the accuracy of claims data and the 
cancer registry files. There can be mistakes in the billing 
data and registry files, but Medicare data are a reliable and 
efficient source of data to study medical care among elderly 
cancer patients (9,27), and cancer registries are among the 
best source of cancer case identification for population 
research (12,28,29).
In conclusion, diabetes management care for cancer 
patients declined after diagnosis, regardless of where 
they received their cancer surgery. This reflects a 
missed opportunity to connect diabetic cancer patients 
to diabetes care, particularly among patients treated in 
large comprehensive cancer centers. This study provides 
benchmarks against which to measure improvements in 
comorbidity management among cancer patients. 
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Table S1 ICD-9 and CPT codes used to define medical services in linked database
Database Registry site-specific codes ICD-9/nDC medicare HCPCS/CPT medicare
Breast conserving 
surgery (BCS) & 
mastectomy
10-90 BCS: 85.20-23, 85.25 BCS: 19120, 19125, 19126, 19160, 19162, 
19301, 19302 
Mastectomy: 85.33-36, 
85.41-48
Mastectomy: 19180, 19182, 19200, 19220, 
19240, 19303, 19304, 19305, 19306, 19307, 
19340, 19342
Colorectal surgery/
sampling & removal
10-90 Removal: 45.25-45.27, 
45.41-45.43, 45.49, 
48.24-48.26, 48.31-48.36, 
48.8x
Non-oncological sampling and removal: 44025, 
45355, 44110, 44389, 44392, 44393, 44394, 
45378, 45380, 45384, 45385, 45392, 45383
Resection: 45.71-76, 
45.79, 45.8×, 48.69, 
48.41, 48.49, 48.5×, 
48.6×, 48.61-65, 45.8×, 
46.01-24, 48.5×, 46.50-52
Resection: 44140, 44141, 44143, 44144, 
44145, 44146, 44147, 44160, 44204, 44025, 
44206, 44207, 44208, 45110, 45111, 45112, 
45113, 45114, 45116, 45119, 45120, 45121, 
45123, 45126, 44150, 44151, 44152, 44153, 
44155, 44156, 44210, 44211, 44212, 44310, 
44316, 44300, 44320, 44322, 44605, 45136, 
45563, 50810, 44620, 44625, 44626
HbAlc testing 83036, 83037, 3044F, 3045F, 3046F, 3047F
LDL-C test 80061, 83700, 83701, 83704, 83721, 3048F, 
3049F, 3050F
Dilated retinal eye exam 14.1×, 14.2×, 14.3×, 
14.4×, 14.5×, 14.9×, 
95.02-04, 95.11-12, 
95.16; diagnosis: V720
67028, 67030, 67031, 67036, 67038, 67039, 
67040, 67041, 67042, 67043, 67101, 67105, 
67107, 67108 67110 67112, 67113, 67121, 
67141, 67145, 67208, 67210, 67218, 67220, 
67221 67227, 67228, 92002, 92004, 92012, 
92014, 92018, 92019, 92225, 92226, 92230, 
92235, 92240, 92250, 92260
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